RT Journal Article
T1 Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature.
A1 Cano, Angela
A1 Guzman-Puche, Julia
A1 Garcia-Gutierrez, Manuel
A1 Caston, Juan Jose
A1 Gracia-Ahufinger, Irene
A1 Perez-Nadales, Elena
A1 Recio, Manuel
A1 Natera, Alejandra M
A1 Marfil-Perez, Eduardo
A1 Martinez-Martinez, Luis
A1 Torre-Cisneros, Julian
K1 Carbapenems
K1 Ceftazidime/avibactam-resistance
K1 Klebsiella pneumoniae
AB To describe the case of a patient with infection due to a KPC-producing Klebsiella pneumoniae (K. pneumoniae) isolate developing ceftazidime-avibactam resistance with restored carbapenem susceptibility during ceftazidime-avibactam therapy. To review the clinical/microbiological cure and survival rates using carbapenems in other similar case reports and case series. A patient with an intra-abdominal infection due to K. pneumoniae producing the KPC-48 variant (L169P-A172T) (resistant to ceftazidime/avibactam and susceptible to carbapenems) who was treated with imipenem-cilastatin in combination with tigecycline and gentamicin. The literature was reviewed in order to summarise the in vivo (clinical/microbiological cure and survival rate) use of carbapenems in this emerging scenario. The patient was successfully treated with the indicated regimen. In other reported cases (mostly with pneumonia) all-cause mortality was 50% and clinical cure was 62.5%. Meropenem-vaborbactam has been successful used in an additional case. A carbapenem-based regimen of combination therapy seems to be an option for treating patients infected with K. pneumoniae resistant to ceftazidime/avibactam and susceptible to carbapenems, at least when the risk of mortality is low.
PB Elsevier
YR 2019
FD 2019-11-06
LK http://hdl.handle.net/10668/14699
UL http://hdl.handle.net/10668/14699
LA en
NO Cano Á, Guzmán-Puche J, García-Gutiérrez M, Castón JJ, Gracia-Ahufinger I, Pérez-Nadales E, et al. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. J Glob Antimicrob Resist. 2020 Sep;22:9-12
DS RISalud
RD Apr 11, 2025